Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0C2HF
|
||||
Former ID |
DIB010274
|
||||
Drug Name |
GR-253035
|
||||
Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Discontinued in Phase 1 | [546666] | ||
Company |
Glaxo Wellcome plc
|
||||
CAS Number |
CAS 215522-99-9
|
||||
Target and Pathway | |||||
Target(s) | Prostaglandin G/H synthase 2 | Target Info | Modulator | [544016] | |
KEGG Pathway | Arachidonic acid metabolism | ||||
Metabolic pathways | |||||
NF-kappa B signaling pathway | |||||
VEGF signaling pathway | |||||
TNF signaling pathway | |||||
Retrograde endocannabinoid signaling | |||||
Serotonergic synapse | |||||
Ovarian steroidogenesis | |||||
Oxytocin signaling pathway | |||||
Regulation of lipolysis in adipocytes | |||||
Leishmaniasis | |||||
Pathways in cancer | |||||
Chemical carcinogenesis | |||||
MicroRNAs in cancer | |||||
Small cell lung cancer | |||||
PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.